Our wholly-owned anti-IL-27 mAb, SRF388, the most advanced program of its kind, was observed to block IL-27 signaling and downstream immunosuppression and also demonstrated preclinical anti-metastatic tumor activity. https://t.co/PpmkgDjyFA
#Il27Insights #biotech